<span>Expediting timelines and enhancing quality for central labs global study startup</span>
June 7, 2021

Expediting timelines and enhancing quality for central labs global study startup

For drug development sponsors running global studies, each day on the path to market is precious. To help support sponsors’ accelerated study startup, our Central Laboratory Services (CLS) has enhanced its core systems and technologies to significantly trim typical startup timelines up to four weeks, reduce the time to implement potential study modifications after startup up to two weeks, and improve the overall quality of delivery.
<span>Exploring Decentralized Clinical Trials (DCTs) – a new monthly blog series</span>
September 1, 2022

Exploring Decentralized Clinical Trials (DCTs) – a new monthly blog series

Welcome to the Decentralized Clinical Trials (DCTs) monthly blog.With patient-centric trial designs becoming a driving force in the drug development industry, we will be doing a series of monthly blogs that look back on recent events which give us insight into designing resilient clinical trials and ensuring study and data continuity. 
<span>Using LC-MS/MS to optimize the OECD 456 H295R steroidogenesis assay for sensitive and selective detection</span>
June 7, 2021

Using LC-MS/MS to optimize the OECD 456 H295R steroidogenesis assay for sensitive and selective detection

Assessing in vitro steroidogenesis endpoints is an important early step in establishing the endocrine disruptor (ED) potential of your crop protection product. Many regulators worldwide now require this information as part of the registration and approval process; for example, in the E.U., the updated pesticide and biocide directives now requests information on ED potential to be included. OECD test number 456 provides in vitro mechanistic information about the impact of a chemical on steroidogenesis and this can determine if subsequent in vivo studies are needed. A reliable, sensitive and selective analytic methodology for measuring steroid hormones is, therefore, a prerequisite for success with OECD 456 – read on to find out how such a method has been optimized by using high-end technology platforms.
<span>Business continuity: how robust is your patient support disaster relief plan?</span>
June 7, 2021

Business continuity: how robust is your patient support disaster relief plan?

To drive speed to therapy, reduce financial burdens and empower patient engagement, a Patient Support Services Call Center provides myriad support services that stakeholders depend upon. For pharmaceutical manufacturers, these services have gone from “nice to have” to “must-have,” driven by the growth of specialty pharmaceuticals. The complexity of treatment, advances in genetic and diagnostic testing and the high cost of specialty products require highly trained personnel, operation efficiencies and the flexibility to scale in lock-step with a product’s life-cycle stage or market conditions.